PDSB earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -1.07. Updated 2026-07-23.
PDS Biotechnology (PDSB) Research Hub
PDS Biotechnology (PDSB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.2949 USD (+0.65%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.07, market cap 0.04B. This hub links to the full technical, earnings and options research available for PDSB.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.2949 USD (+0.65%) |
| 52-week range | 0.1952 USD – 1.14 USD |
| Trend regime | Range |
| 14-day RSI | 16.7 (Oversold) |
| Trailing P/E | -1.07 |
| Market cap | 0.04B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for PDSB
Covered Call on PDSB: how it works, illustrative setup around the real 0.2949 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PDSB: how it works, illustrative setup around the real 0.2949 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PDSB: how it works, illustrative setup around the real 0.2949 USD price, max profit/loss, breakeven and when to use it. Educational.
PDSB technical analysis: range, last 0.2949 USD, RSI 16.7, 52w range 0.1952 USD–1.14 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PDSB in?
PDS Biotechnology (PDSB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PDSB in an uptrend or downtrend?
As of 2026-09-11, PDSB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PDSB's trailing P/E ratio?
PDSB's trailing P/E is -1.07, with a market cap of 0.04B. See the earnings research page for full valuation detail.
When does PDSB next report earnings?
PDSB is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.13 USD.